JP2023538859A - レボドパ送達のための組成物及び方法 - Google Patents

レボドパ送達のための組成物及び方法 Download PDF

Info

Publication number
JP2023538859A
JP2023538859A JP2023509769A JP2023509769A JP2023538859A JP 2023538859 A JP2023538859 A JP 2023538859A JP 2023509769 A JP2023509769 A JP 2023509769A JP 2023509769 A JP2023509769 A JP 2023509769A JP 2023538859 A JP2023538859 A JP 2023538859A
Authority
JP
Japan
Prior art keywords
levodopa
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538859A5 (https=
Inventor
フー ファン，ハイヨン
シェト，マンジュナス，エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of JP2023538859A publication Critical patent/JP2023538859A/ja
Publication of JP2023538859A5 publication Critical patent/JP2023538859A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023509769A 2020-08-31 2021-08-30 レボドパ送達のための組成物及び方法 Pending JP2023538859A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072661P 2020-08-31 2020-08-31
US63/072,661 2020-08-31
PCT/US2021/048218 WO2022047298A1 (en) 2020-08-31 2021-08-30 Compositions and methods for levodopa delivery

Publications (2)

Publication Number Publication Date
JP2023538859A true JP2023538859A (ja) 2023-09-12
JP2023538859A5 JP2023538859A5 (https=) 2024-09-05

Family

ID=80354133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509769A Pending JP2023538859A (ja) 2020-08-31 2021-08-30 レボドパ送達のための組成物及び方法

Country Status (4)

Country Link
US (1) US20230181508A1 (https=)
EP (1) EP4203939A4 (https=)
JP (1) JP2023538859A (https=)
WO (1) WO2022047298A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527447A (ja) * 2009-05-19 2012-11-08 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
JP2013545745A (ja) * 2010-11-15 2013-12-26 ニューロダーム リミテッド Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
JP2016512230A (ja) * 2013-03-13 2016-04-25 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
US20180344951A1 (en) * 2014-11-09 2018-12-06 Sipnose Ltd. Device and method for aerosolized delivery of substance to a natural orifice of the body
WO2019136306A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of levodopa power by precision olfactory device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2010009557A1 (en) * 2008-07-25 2010-01-28 Sanomune Inc. Tissue kallikrein for the treatment of parkinson's disease
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US11806326B2 (en) * 2018-01-29 2023-11-07 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527447A (ja) * 2009-05-19 2012-11-08 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
JP2013545745A (ja) * 2010-11-15 2013-12-26 ニューロダーム リミテッド Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
JP2016512230A (ja) * 2013-03-13 2016-04-25 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
US20180344951A1 (en) * 2014-11-09 2018-12-06 Sipnose Ltd. Device and method for aerosolized delivery of substance to a natural orifice of the body
WO2019136306A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of levodopa power by precision olfactory device

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 38, JPN6025029364, 2009, pages 525 - 532, ISSN: 0005646005 *
US NEUROLOGY, vol. 16, no. 1, JPN6025029363, 2020, pages 25 - 31, ISSN: 0005646004 *

Also Published As

Publication number Publication date
EP4203939A1 (en) 2023-07-05
EP4203939A4 (en) 2024-11-06
US20230181508A1 (en) 2023-06-15
WO2022047298A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP5683719B2 (ja) ベポタスチン組成物
US8859531B2 (en) Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
EP1980271A1 (en) Medicine for transnasal administration
US11389441B2 (en) Ophthalmic compositions
US11529333B2 (en) Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
JP2011500577A (ja) バルサルタンの医薬製剤
US20090221563A1 (en) Oral suspension comprising meloxicam
US20260070872A1 (en) Compounds and methods for treating inflammatory disorders
EP2931249B1 (en) Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
TWI589305B (zh) 用於經口投藥之包含安布索、左旋羥丙哌嗪及緩衝劑的液體調配物以及製備其之方法
US20140024720A1 (en) Pharmaceutical composition containing cyclobenzaprine suitable to intranasal administration
JP2023538859A (ja) レボドパ送達のための組成物及び方法
KR20080015429A (ko) 에스리카르바제핀 아세테이트 및 그의 사용방법
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
US20060193784A1 (en) Scopolamine sublingual spray for the treatment of motion sickness
JP2011011984A (ja) 仮性近視治療薬
WO2026089753A1 (en) Compositions and methods for intranasal delivery of carnosine for treatment of neurodegenerative diseases and disorders
JP2022501407A (ja) ゾルピデム又はその薬学的に許容される塩の口腔粘膜溶液剤
NZ616149B2 (en) Nasal Pharmaceutical Formulation Comprising Fluticasone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121